MW_Medicina interna ambulatoria_3ed

638

Capítulo 32 • Síndrome del intestino irritable

17. Lacy BE, Pimentel M, Brenner DM, et al. ACG Clinical Guideline: Management of Irri table Bowel Syndrome. Am J Gastroenterol 2021;116:17–44. 18. Drossman DA, Chey WD, Johanson JF, et al. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome—results of two randomized, placebo-con trolled studies. Aliment Pharmacol Ther 2009;29:329–341. 19. Busby RW, Kessler MM, Bartolini WP, et al. Pharmacologic properties, metabolism, and disposition of linaclotide, a novel therapeutic peptide approved for the treatment of irri table bowel syndrome with constipation and chronic idiopathic constipation. J Pharmacol Exp Ther 2013;344:196–206. 20. Chey WD, Lembo AJ, Lavins BJ, et al. Linaclotide for irritable bowel syndrome with con stipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate effi cacy and safety. Am J Gastroenterol 2012;107:1702–1712. 21. Vakil N. Commentary: tegaserod and IBS, two decades on. Aliment Pharmacol Ther 2020;51:200–201. 22. Chey WD, Lembo AJ, Yang Y, et al. Efficacy of tenapanor in treating patients with irritable bowel syndrome with constipation: a 26-week, Placebo-Controlled Phase 3 Trial (T3MPO 2) . Am J Gastroenterol 2021;116(6):1294–1303. 23. Camilleri M, Vijayvargiya P. The role of bile acids in chronic diarrhea. Am J Gastroenterol 2020;115:1596–1603. 24. Andresen V, Montori VM, Keller J, et al. Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials. Clin Gas troenterol Hepatol 2008;6:545–555. 25. Lembo AJ, Lacy BE, Zuckerman MJ, et al. Eluxadoline for irritable bowel syndrome with diarrhea. N Engl J Med 2016;374:242–253. 26. Black CJ, Yuan Y, Selinger CP, et al. Efficacy of soluble fibre, antispasmodic drugs, and gut-brain neuromodulators in irritable bowel syndrome: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol 2020;5:117–131. 27. Billings W, Mathur K, Craven HJ, et al. Potential benefit with complementary and alter native medicine in irritable bowel syndrome: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2021;19(8):1538–1553.e14. 28. Pimentel M, Lembo A, Chey WD, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011;364:22–32. 29. Lembo A, Pimentel M, Rao SS, et al. Repeat treatment with rifaximin is safe and effec tive in patients with diarrhea-predominant irritable bowel syndrome. Gastroenterology 2016;151:1113–1121. 30. Ford AC, Quigley EM, Lacy BE, et al. Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. Am J Gastroenterol 2014;109:1547–1561. 31. Ford AC, Lacy BE, Harris LA, et al. Effect of antidepressants and psychological therapies in irritable bowel syndrome: an updated systematic review and meta-analysis. Am J Gastro enterol 2019;114:21–39. 32. Spiller R. Impact of diet on symptoms of the irritable bowel syndrome. Nutrients 2021;13:575. SAMPLE